CFRA Research Becomes Exclusive Global Equity Research Provider for Geneva-Based Banque Audi Suisse
5.12.2024 11:00:00 CET | Business Wire | Press release
Exclusive partnership expands access to global equity research for Bank Audi Suisse team of investment professionals through CFRA’s industry-leading MarketScope Advisor Platform.
CFRA, the world’s leading provider of independent investment research today announced that its global fundamental equity, thematic, and sector research is now available to Banque Audi Suisse investment professionals and relationship managers, exclusively through their MarketScope Advisor platform.
The partnership provides Banque Audi Suisse with real-time access to CFRA’s industry-leading research and analytical tools to help their investment teams stay on top of changes in global markets, make well-informed investment decisions, and deliver value to their affluent client base.
"Our search for a global equity research provider was driven by our commitment to delivering maximum value to our client base,” said Hans Itburrun, Head of Investments for Banque Audi Suisse. “It was critical that the partner we chose be able to provide a comprehensive global view of equity markets, had a strong foundation of U.S. coverage, and was backed by a strong track record of performance, CFRA easily checked all those boxes and was able to deliver their research to our team through a turnkey, easy-to-use platform.”
"We are delighted to be selected as the exclusive provider of global equity research to Banque Audi Suisse,” says Patricia Wilson, Chief Solutions Officer for CFRA. “This strategic partnership is an important step in our focus on the Swiss market and underscores the value our research and technology offering for private banks and their clients.”
With decades of experience providing unbiased and actionable research, CFRA’s equity research is trusted globally by more than 150,000 financial advisors and relationship managers through its industry-leading MarketScope Advisor platform.
ABOUT CFRA
A global leader in financial intelligence solutions and insights, CFRA blends a proprietary mix of fundamental equity, forensic accounting, fund, public policy/legal, and technical research with data, analytics, and next-gen technology to arm clients with the financial intelligence required to meet their business and investing goals.
Learn more about CFRA Research and their MarketScope Advisor platform.
ABOUT BANQUE AUDI SUISSE
Banque Audi (Suisse) SA was first established in Zurich in 1976. Its headquarters were later relocated to Geneva, close to the city’s historic Old Town and famous lake. Operating under a Swiss banking license and under the supervision of the Swiss Financial Market Supervisory Authority (FINMA), Banque Audi Suisse offers tailor-made Private Banking services to high-net-worth clients, with access to products and foreign exchange markets all over the world.
In the latest study of November 2024 of Zurich University of Applied sciences (ZHAW) on the Best Private Banks in Switzerland in 2024, Banque Audi Suisse has been ranked as the “Best Capitalized Swiss Private Bank 2024”.
Learn more about Banque Audi Suisse.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205074954/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom